Cephalon, an international biopharmaceutical company, has acquired Swiss-based pharmaceutical company Mepha. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon.
Cephalon said that the purchase price paid at closing, inclusive of certain closing adjustments, was CHF662.4m. The purchase price is also subject to further post-closing working capital and net debt adjustments.
Frank Baldino, chairman and CEO of Cephalon, said: “We are proud to include Mepha as part of the Cephalon family. This acquisition expands our presence in Europe, and we believe Mepha will contribute to our long-term growth.”
Alain Aragues, executive vice president and president of Cephalon Europe, said: “We are pleased to add Mepha’s experience and expertise, which are critical to our successful development of a balanced business mix in Europe, Middle East and Africa.
“Cephalon intends to leverage Mepha’s brand recognition as the number one generics company in Switzerland and a prominent generic pharmaceutical company in many other markets.”